MARKET

MRNA

MRNA

Moderna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

149.96
+7.11
+4.97%
Opening 15:41 07/01 EDT
OPEN
141.93
PREV CLOSE
142.85
HIGH
151.02
LOW
139.54
VOLUME
4.05M
TURNOVER
382.38M
52 WEEK HIGH
497.49
52 WEEK LOW
115.61
MARKET CAP
59.65B
P/E (TTM)
4.409
1D
5D
1M
3M
1Y
5Y
UPDATE 1-Omicron-specific COVID shots could increase protection as boosters - EMA
UPDATE 1-Omicron-specific COVID shots could increase protection as boosters - EMA
Reuters · 6h ago
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
Benzinga · 7h ago
BRIEF-Moderna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global News
BRIEF-Moderna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global News
Reuters · 23h ago
Moderna Inc. stock outperforms competitors on strong trading day
marketwatch.com · 23h ago
Omicron: Experts want more data to guide US targeting of fall boosters
The FDA is asking COVID-19 vaccine makers to test and produce boosters that target both the original and new BA.4/BA.5 strains of the virus by fall.
Yahoo Finance · 1d ago
The FDA Just Handed BioNTech And Moderna A Gift — But Only One Jumped
The FDA requested vaccine makers update their Covid shots to include an omicron-fighting element on Thursday, and BNTX stock surged.
Investor's Business Daily · 1d ago
Supreme Court Allows New York Vaccine Mandate for Health-Care Workers
(Bloomberg) -- The US Supreme Court turned away a challenge to New York’s Covid-19 vaccine requirement for health-care workers, rejecting an appeal from 16 people who objected to the shot on religious grounds.Most Read from BloombergDemocrats Weigh Paring ...
Bloomberg · 1d ago
FDA says COVID-19 boosters should be updated to combat two omicron subvariants
The Food and Drug Administration on Thursday told COVID-19 vaccine makers that plan to update their boosters to add a BA.4 and BA.5 spike protein component to the new shots that are in development. These "bivalent" boosters should equally target the two su...
marketwatch.com · 1d ago
More
No Data
Learn about the latest financial forecast of MRNA. Analyze the recent business situations of Moderna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

10.00%Strong Buy
35.00%Buy
50.00%Hold
5.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRNA stock price target is 219.33 with a high estimate of 506.00 and a low estimate of 70.00.
High506.00
Average219.33
Low70.00
Current 150.02
EPS
Actual
Estimate
2.825.648.4711.29
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.12K
Institutional Holdings: 253.82M
% Owned: 63.81%
Shares Outstanding: 397.76M
TypeInstitutionsShares
Increased
392
16.66M
New
122
1.99M
Decreased
316
14.57M
Sold Out
214
1.71M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.81%
Pharmaceuticals & Medical Research
+0.78%
Key Executives
Non-Executive Chairman/Independent Director
Noubar Afeyan
President
Stephen Hoge
Chief Executive Officer/Director
Stephane Bancel
Chief Financial Officer
David Meline
Chief Human Resource Officer
Tracey Franklin
Chief Technology Officer
Juan Andres
Other
Paul Burton
Other
Kate Cronin
Other
Marcello Damiani
Secretary
Shannon Klinger
Independent Director
Stephen Berenson
Independent Director
Sandra Horning
Independent Director
Robert Langer
Independent Director
Elizabeth Nabel
Independent Director
Francois Nader
Independent Director
Paul Sagan
Independent Director
Elizabeth Tallett
No Data
No Data
About MRNA
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Webull offers kinds of Moderna Inc stock information, including NASDAQ:MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.